+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure



High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure



Journal of the American College of Cardiology 36(5): 1587-1593, November 1



OBJECTIVES: The aim of this study was to evaluate whether repetitive measurements of plasma levels of neurohumoral factors and cytokines before and after additional treatment are useful for predicting mortality in patients with congestive heart failure (CHF). BACKGROUND: Neurohumoral and immune activation play an important role in the pathophysiology of CHF. However, the effects of serial changes in these factors on the prognostic value remain unknown. METHODS: We measured plasma levels of neurohumoral factors and cytokines and left ventricular ejection fraction (LVEF) before and three months after optimized treatment for CHF in 102 consecutive patients with severe CHF (New York Heart Association class III to IV) on admission to our hospital. Physicians who were blind to the plasma neurohumoral factors until study completion treated patients using standard drugs. Patients were monitored for a mean follow-up period of 807 days. RESULTS: Plasma levels of neurchumoral factors, cytokines and LVEF were significantly improved three months after optimized treatment. Cardiac death occurred in 26 patients. Among 19 variables including LVEF, only a high level of bain natriuretic peptide (BNP) and interleukin-6 (IL-6) at three months after optimized treatment showed significant independent relationships by Cox proportional hazard analysis with a high mortality for patients with CHF. CONCLUSIONS: These findings indicate that high plasma BNP and IL-6 levels three months after optimized treatment are independent risk factors for mortality in patients with CHF, suggesting that sustained high plasma levels of BNP and IL-6 after additional standard treatment were independent risk factors for mortality in patients with CHF despite improvements in LVEF and symptoms.

(PDF emailed within 0-6 h: $19.90)

Accession: 010750117

Download citation: RISBibTeXText

PMID: 11079662

DOI: 10.1016/s0735-1097(00)00912-8


Related references

High levels of plasma brain natriuretic peptide and interleukin-6 after treatment are independent risk factors for mortality in patients with congestive heart failure. Circulation 100(18 SUPPL ): I 679, Nov 2, 1999

Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. Journal of Heart and Lung Transplantation 23(7): 839-844, 2004

High level of plasma BNP at discharge is an independent risk factor for mortality and morbidity in patients with congestive heart failure. Journal of the American College of Cardiology 33(2 SUPPL A): 192A, 1999

Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Journal of the American College of Cardiology 56(25): 2090-2100, 2011

High levels of plasma soluble apoptosis mediators after treatment are independent risk factors for mortality in chronic heart failure patients. European Heart Journal 22(Abstract Supplement): 398, 2001

Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation 134(22): 1785-1787, 2018

Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. International Heart Journal 46(3): 465-475, 2005

Plasma brain natriuretic peptide concentration as a useful predictor of mortality and morbidity in patients with diastolic heart failure. Circulation 102(18 Supplement): II 624, October 31, 2000

Positive pressure ventilation treatment reduces plasma levels of amino terminal-pro brain natriuretic peptide in congestive heart failure patients with sleep apnea. Circulation Journal 70(5): 572-574, 2006

High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. Congestive Heart Failure 9(3): 127-132, 2003

Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. Circulation. Heart Failure 9(11), 2016

The Effect of Angiotensin-Converting-Enzyme Inhibition on Plasma Brain Natriuretic Peptide Levels in Congestive Heart Failure Patients. Clinical Science 83(S27): 9p.3-9p, 1992

Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure. Plos One 13(11): E0206380, 2018

Plasma levels of brain natriuretic peptide, cyclic 3'5'-guanosine monophosphate, endothelin 1, and noradrenaline in patients with chronic congestive heart failure. Polskie Archiwum Medycyny Wewnetrznej 109(1): 43-48, 2003

Plasma levels of atrial natriuretic peptide at peak exercise A prognostic marker of cardiac mortality and transplantation in patients with stable congestive heart failure. European Heart Journal 16(ABSTR SUPPL ): 49, 1995